• For the treatment of essential hypertension.
• For the treatment of heart failure (NYHA class II-IV) reduced hospitalization for heart failure.
• For the treatment of reduction of cardiovascular mortality in clinically stable patients withleft ventricular failure or left ventricular dysfunction following myocardial infarction.